P554: GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY FOR RELAPSED/REFRACTORY FLT3‐MUTATED ACUTE MYELOID LEUKEMIA: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN‐LABEL TRIAL IN ASIA | Zendy

Wang J. | Zendy; Jiang B. | Zendy; Li J. | Zendy; Liu L. | Zendy; Du X. | Zendy; Jiang H. | Zendy; Hu J. | Zendy; Yuan M. | Zendy; Sakatani T. | Zendy; Kadokura T. | Zendy; Takeuchi M. | Zendy; Izuka S. | Zendy; Girshova L. | Zendy; Tan J. | Zendy; Bondarenko S. | Zendy; Wong L. L. L. | Zendy; Khuhapinant A. | Zendy; Martynova E. | Zendy; Hasabou N. | Zendy; Tiu R. | Zendy

Open Access

P554: GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY FOR RELAPSED/REFRACTORY FLT3‐MUTATED ACUTE MYELOID LEUKEMIA: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN‐LABEL TRIAL IN ASIA

Author(s) -

Wang J.,

Jiang B.,

Li J.,

Liu L.,

Du X.,

Jiang H.,

Hu J.,

Yuan M.,

Sakatani T.,

Kadokura T.,

Takeuchi M.,

Izuka S.,

Girshova L.,

Tan J.,

Bondarenko S.,

Wong L. L. L.,

Khuhapinant A.,

Martynova E.,

Hasabou N.,

Tiu R.

Publication year - 2022

Publication title -

hemasphere

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.677

H-Index - 11

ISSN - 2572-9241

DOI - 10.1097/01.hs9.0000845104.07004.2e

Subject(s) - medicine , tolerability , cytarabine , fludarabine , clinical endpoint , surgery , mitoxantrone , population , hazard ratio , myeloid leukemia , interim analysis , salvage therapy , gastroenterology , chemotherapy , randomized controlled trial , adverse effect , cyclophosphamide , confidence interval , environmental health

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog